This browser is no longer supported

Please switch to a supported browser to continue using this website.
Consider using the latest version of Google Chrome or Microsoft's Edge to view this website.

Annual Reports

View our online annual report 2021

 

Key Business Performance and Highlights

CSL Growth Icon
Focus
  • Remained focused on delivering on our promise to patients and public health during an unprecedented time of uncertainty.
  • US$20.2 million supporting product access across the world.*
CSL Growth Icon
Innovation
  • Research and development (R&D) investment of US$1 billion.*
  • Acquired the exclusive global licence rights to a late stage gene therapy candidate for the treatment of haemophilia B.
  • CSL112 (currently in Phase III for cardiovascular disease) continues to progress with over 13,000 patients enrolled.
  • Commenced a Phase II study for an adjuvanted QIV cell-based influenza vaccine.
  • Accelerated research into self-amplifying mRNA technology to develop the potential next generation of influenza vaccines.
  • Achieved 28 product registrations or new indications across the globe.
  • US$55.2 million in global community investment across our strategic areas of support.
CSL Growth Icon
Efficiency and reliable supply
  • Ongoing investment in major capital projects at all manufacturing sites to support future growth.
  • In 2020/21, 25 new plasma collection centres opened.
  • Record number of influenza vaccine doses distributed by Seqirus.
  • Delivering on our agreements to supply 50 million doses of the AstraZeneca COVID-19 vaccine.
  • Participated in 365 successful regulatory inspections of our manufacturing facilities.*
CSL Growth Icon
Sustainable growth
  • A strong year of growth with revenue up 10% and reported net profit after tax of $2,375 million, up 10% at constant currency.
  • Strong performance by HIZENTRA®, our market leading subcutaneous immunoglobulin product with sales up 15%.
  • Seqirus revenue up 30% at constant currency driven by strong growth in seasonal influenza vaccines.
  • US$9.9 billion distributed in supplier payments, employee wages and benefits, shareholder returns, government taxes and community contributions.*
  • Release of CSL Group Sustainability Strategy.
CSL Growth Icon
Digital transformation
  • Appointment of Chief Digital and Information Officer.
  • New initiatives and technology implemented at plasma collection centres.
  • New enterprise-wide digital platform rollout.
CSL Growth Icon
People and culture
  • Achieved 73.7% employee engagement* score, on par with the previous year.
  • 43% female representation at Board level, 57% female across the Group.
  • Launched a new Promising Futures Scholarship Program to provide financial assistance to US employees and their dependants.

Annual Report Archive

..

Introduction to CSL

See how we are driven by our promise.

Learn More

Board and Management

View our Board and Management here.

Learn More

Corporate Governance

View our corporate governance here.

Learn More